References
- Cancer in Slovenia 2007. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2010.
- Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl Med 2005; 352: 476-87.
- Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study. Radiol Oncol 2008; 42: 207-14.
- Velenik V. Post-treatment surveillance in colorectal cancer. Radiol Oncol 2010; 44: 135-41.
- National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: colon cancer. V.3.2011 (on line). Avaible: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf
- Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol 2010; 21: v93-7.
- Kohne CH. How to integrate molecular targeted agents in the continuum of care. Ann Oncol 2010; 21: vii134-9.
- Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.
- Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transducting pathways in colorectal cancer-More than skin deep. J Clin Oncol 2005; 23: 5374-85.
- Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
- Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9.
- Etienne-Grimaldi M-C, Formento J-L, Francoual M, François E, Formento P, Renée N, et al. K- Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008; 14: 4830-5.
- Ličar A, Cerkovnik P, Ocvirk J, Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010, 36: 1137-44.
- De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy- refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20.
- Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild- type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
- Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466-74.
- Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Kohne C, et al. The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus folfiri. [Abstract]. Ann Oncol 2008; 19(Suppl 6): vi17-8.
- Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.
- Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2010 Jul 20. [Epub ahead of print]
- De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
- Tejpar S, De Roock W. PIK13CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. Eur J Cancer 2009; 7: 322.
- Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a marker of resistence of cetuximab in chemorefractory metastatic colorectal cancer. [abstract] J Clin Oncol 2009; 27 (Suppl): 172.
- Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
- Kohne CH, Rougier P, Stroh C, Schlichting M, Bokemeyer C, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st- line treatment for metastatic colorectal cancer: A meta- analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO GI 2010 [abstract 406].
- Bookemeyer C, Kohne CH, Rougier P, Stroh C, Schlichting M, Van Cutsem E, et al. Cetuximab with chemotherapy as 1st- line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract]. J Clin Oncol 2010; 28 (Suppl): 3506.
- Tejpar S, Bukemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E, et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first- line chemotherapy with or without cetuximab. ASCO 2011 [abstract 3511].
- Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21.
- Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR, et al. Activating K-ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumoursimplications for personalised cancer medicine. Br J Cancer 2010; 102: 1-11.
- Okines A, Del Puerto O, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-8.
- Terrebonne E, Smith D, Becouarn Y, Michel P, Guimbaud M, Fourrier- Reglat A, et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first- line therapy: results of the ETNA cohort study (abstract 3594). J Clin Oncol 2010; 28: (Suppl.):15s.
- Ocvirk J, Rebersek M, Boc M. Bevacizumab in first- line therapy of meta-static colorectal cancer: A retrospective comparison of FOLFIRI and XELIRI. Anticancer Res 2011; 31: 1777-82.
- Wong R, Cunningham D, Barbachano Y, et al. A multicentric study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor- risk colorectal liver- only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-8.
- Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
- Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with or without cetuximab in the first- line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
- Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 1: 38-47.
- Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5- fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1-6.